Unveiling the synergy of AI’s regulatory harmony in shaping the future of biopharmaceutical progress

By Baily Thomas, Madison Burns, Danielle Helton Corwin and Eddie Reilly2024-04-03T12:00:00

In this article, we consider how artificial intelligence (AI) is not merely an auxiliary tool but an essential partner in the biopharmaceutical industry’s pursuit of innovative therapies and life-changing medications. It has the potential to bring about a paradigm shift in the way that novel treatments are discovered and delivered. However, proactive measures, including establishing clear standards for data quality and collaborative efforts in regulatory frameworks, are pivotal steps toward realising the full benefits of AI in biopharmaceuticals.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

1. REGISTER FOR FREE

Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

Create your own library to save your favourite content.

Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

3. JOIN TOPRA

Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member